3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Active not recruiting
2
Sponsor Class
OTHER
2
NETWORK
1
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
181
Lymphoma
97
Lymphoma, Large B-Cell, Diffuse
96
Precursor Cell Lymphoblastic Leukemia-Lymphoma
79
Sarcoma
69
Hodgkin Disease
54
Lymphoma, Non-Hodgkin
41
Triple Negative Breast Neoplasms
37
Burkitt Lymphoma
36
Lymphoma, Mantle-Cell
32
Leukemia
32
Lymphoma, Follicular
30
Multiple Myeloma
28
Carcinoma, Hepatocellular
28
Neoplasm Metastasis
23
Ovarian Neoplasms
21
Neoplasms
21
Lymphoma, Large-Cell, Anaplastic
18
Osteosarcoma
17
Lymphoma, B-Cell
17
Prostatic Neoplasms
16
Neuroblastoma
15
Lymphoma, T-Cell, Peripheral
15
Urinary Bladder Neoplasms
14
Recurrence
13
Lymphoma, Large-Cell, Immunoblastic
13
Inflammatory Breast Neoplasms
13
Immunoblastic Lymphadenopathy
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
11
Stomach Neoplasms
10
Interventions
Surgical Procedures, Operative
2
Paclitaxel
2
Doxorubicin
2
Cyclophosphamide
2
Carboplatin
2
pertuzumab
1
liposomal doxorubicin
1
cemiplimab
1
atezolizumab
1
Trastuzumab
1
Radiotherapy
1
Magnetic Resonance Spectroscopy
1
Indocyanine Green
1
Anastrozole
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Invasive Breast Cancer
×
Doxorubicin
×
Clear all
NCT04243616
2025-09-05
CemiHALT
Medical College of Wisconsin
Phase 2
Active not recruiting
36 enrolled
NCT03595592
2024-03-06
APTneo
Fondazione Michelangelo
Phase 3
Active not recruiting
650 enrolled